GW's Epidiolex Epilepsy Data Paves Way For Cannabinoids
Executive Summary
Safety and efficacy in study published in New England Journal of Medicine bode well for cannabinoid therapy Epidiolex, which is headed to FDA mid-year.
You may also be interested in...
Zogenix’s Fintepla Reduces Drop Seizure Rates, But Is It Enough?
Despite positive Phase III results in Lennox-Gastaut syndrome, the effect of the company’s low-dose fenfluramine on serious seizures may not be as good as seen with GW Pharma’s Epidiolex.
Dravet Syndrome: A Rare Epilepsy, Now With Two Approved Treatments
Biocodex's Diacomit – long approved in the EU – just won FDA approval. That brings the number of drugs cleared for Dravet in the US to two, including GW Pharma's recently endorsed Epidiolex, and the R&D pipeline for this rare seizure disorder is growing.
The Year's Clinical Trials In Review: Big Hits In 2017
Scrip takes a trip back through the highs of drug development, looking at successes including positive cardiovascular outcomes studies for cholesterol drugs, advances in cancer and breakthroughs in hemophilia.